Abcellera Biologics Inc (ABCL NASDAQ) stock market data APIs
$12.7202
0.25(2%)
as of October 7, 2026
Try our APIs with
free plan!
Abcellera Biologics Inc Financial Data Overview
Price chart is built with
Anychart
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Prev. Close
12.7202
Open
12.9692
High
13.3912
Low
12.6316
52 wk Range
2.745-15.015
Market Cap
4 261 M
Shares Outstanding
324 M
Revenue
66 170 K
EPS
-0.18
Beta
1.41
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Abcellera Biologics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Abcellera Biologics Inc data using free add-ons & libraries
Get Abcellera Biologics Inc Fundamental Data
Abcellera Biologics Inc Fundamental data includes:
- Net Revenue: 66 170 K
- EBITDA: -199 960 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-05
- EPS/Forecast: -0.17
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Abcellera Biologics Inc News
New
AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment
Equity Insider News Commentary AUSTIN, Texas, Oct. 1, 2026 /PRNewswire/ -- Towards Healthcare projects that the global AI in drug discovery market will grow from $19.89 billion in 2025 to $160.49 bil...
Premarket movers: FICO sinks while Summit, AAR and CarMax rise
Investing.com - U.S. stock index futures hovered around the flatline on Tuesday after soaring bond yields dented Wall Street in the prior session, as investors looked ahead to a fresh batch of economi...
ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know
AbCellera Biologics ABCL has delivered a sharp rally over the past three months, with the stock soaring 121% compared with the industry's 6.6% growth. The move has been driven primarily by a combinati...
FDA names acting heads of drug and vaccine units to permanent roles
[FDA Headquarters] The Trump administration on Tuesday appointed the acting heads of the FDA units overseeing drugs, vaccines, and tobacco to permanent positions weeks after nominating White House ad...
Get Abcellera Biologics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.